Complement Therapeutics Ltd announced that it has received 72 million in a round of funding co-led by new investor Gimv NV and returning investor Forbion Capital Partners B.V. on April 17, 2023. The transaction included participation from new investors, Panakès Partners SGR SpA, Cambridge Innovation Capital Limited, Hadean Ventures, Seroba Life Sciences Limited and returning investor, BioGeneration Ventures B.V.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.6 EUR | +1.25% | -0.45% | +0.68% |
Apr. 15 | European Commission OKs Gimv Takeover by WorxInvest | MT |
Apr. 15 | Gimv: EU approves acquisition by WorxInvest | CF |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+0.68% | 1.33B | |
+15.32% | 84.55B | |
+12.36% | 26.01B | |
-6.65% | 17.28B | |
+13.32% | 16.57B | |
+6.74% | 14.28B | |
-16.11% | 13.16B | |
+16.00% | 9.52B | |
+26.11% | 8.75B | |
+27.22% | 7.13B |
- Stock Market
- Equities
- GIMB Stock
- News Gimv NV
- Complement Therapeutics Ltd announced that it has received €72 million in funding from a group of investors